Results 81 to 90 of about 6,511 (194)

Growth hormone deficiency, secondary hypothyroidism, and empty sella following treatment of childhood macroprolactinoma

Indian Journal of Endocrinology and Metabolism, 2013
Macroprolactinoma are rare in childhood, especially in the first decade. A 9-year-old girl presented with headache, vomiting, and decreased vision for 8 months. A diagnosis of macroprolactinoma was made following documentation of elevated serum prolactin
Chitra Selvan, Deep Dutta, Sujoy Ghosh, Satinath Mukhopadhyay, Subhankar Chowdhury   +4 more
doaj   +1 more source

Triage and care for women with symptoms or diagnosis of pregnancy loss between 14 + 0 and 21 + 6 weeks' gestation

International Journal of Gynecology &Obstetrics, Volume 172, Issue 1, Page 25-50, January 2026.
Abstract Mid‐trimester pregnancy loss (MTL), defined as a pregnancy loss occurring between 14 + 0 and 21 + 6 weeks of gestation, causes significant physical and emotional distress to women and presents clinical challenges to healthcare professionals. It is acknowledged that in low‐resource settings, this guideline might be applicable to births up to 28 
Caroline E. Fox, Rosinder Kaur, Kugajeevan Vigneswaran, Rachel Small, Jenny Carter, Keelin O'Donoghue, Alexander E. P. Heazell, Anna L. David, Nigel Simpson, Angharad Care, Lisa Starrs, Andrew Shennan, Catalina María Valencia González, Priya Soma‐Pillay, Leah Fitzsimmons, Adam J. Devall, Arri Coomarasamy, Mid‐trimester Pregnancy Loss Guideline Consensus Panel, Owen Arthurs, Ruth Bender‐Atik, Phil Bennett, Kirstien Boelaert, Elizabeth Bonney, Leanna Brace, Naomi Carlisle, Davide Casagrandi, Manju Chandiramani, Carolyn Chiswick, Alexandra Emms, Stella Fielder, James Goadsby, Laura Goodfellow, Jim Gray, Jemma Johns, Emma Kirk, Will Lester, Sophie Mackay, Maria Memtsa, Katie Morris, Sunbal Mukhtar, Naimah Raza, Rita Sarquis, Neil Sebire, Lucy Smith, Lucy Spencer, Amos Tetteh, Natalie Woodhead   +46 more
wiley   +1 more source

A Novel Case of Spontaneous Coronary Artery Dissection During Cabergoline Therapy for Prolactinoma

JACC: Case Reports, 2020
We present a case of spontaneous coronary artery dissection associated with cabergoline treatment for prolactinoma. A 31-year-old woman with history of hypertension and prolactinoma, treated with cabergoline, presented with chest pain.
Shinichiro Ikeda, MD, Jeffrey Le, MD, Shivani Verma, MD, Benjamin A. Youdelman, MD   +3 more
doaj   +1 more source

A COMPARATIVE STUDY ON THE EFFECTS OF BROMOCRIPTINE AND CABERGOLINE IN FEMALES WITH HYPERPROLACTINEMIC AMENORRHEA

, 2020
Background: Dopamine agonists are the preferred treatment for most patients with hyperprolactinemia disorders. These agents are extremely effective in lowering serum prolactin levels, eliminating galactorrhea, restoring regular menstruation, and reducing
Dr Eijaz Ahmed, Dr Ammara Khaliq, Dr Saqib Nasrullah
core   +1 more source

Giant cabergoline-resistant prolactinoma in a man who presented with a psychotic episode during treatment: a case report

Journal of Medical Case Reports, 2019
Background Prolactinomas are tumors of the pituitary gland that usually respond very well to treatment with cabergoline. Resistance to cabergoline is very rare, but when it occurs, it is a difficult problem to resolve if the tumor is inoperable.
Luiz Augusto Casulari, Lucas Faria de Castro, Iruena Moraes Kessler, José Luiz Mendonça, Maria de Fátima Magalhães Gonzaga   +4 more
doaj   +1 more source

Cabergoline monotherapy in the long-term treatment of Cushing's disease

, 2010
BackgroundCabergoline is a long-acting dopamine receptor agonist used to treat prolactinomas. Identification of D2 receptors in corticotroph tumors led to clinical trials of cabergoline therapy in limited cases of Nelson's syndrome, ectopic ACTH ...
Hugues Beauregard, Marcos Manavela, André Lacroix, Karina Danilowicz, Oscar Domingo Bruno, Ariane Godbout   +5 more
core   +1 more source

Profile of leptin, adiponectin, and body fat in patients with hyperprolactinemia: Response to treatment with cabergoline

Indian Journal of Endocrinology and Metabolism, 2016
Introduction: Though hypoadiponectinemia and leptin resistance have been proposed as potential factors for weight gain in patients with hyperprolactinemia (HPL), the effects of HPL and cabergoline on these adipocyte-derived hormones are not clear.
Nazir Ahmad Pala, Bashir Ahmad Laway, Raiz Ahmad Misgar, Zaffar Amin Shah, Tariq A Gojwari, Tariq A Dar   +5 more
doaj   +1 more source

Multicenter Placebo-Controlled Trial of Cabergoline Taken Once Daily in the Treatment of Parkinson\u27s Disease

, 1996
Cabergoline is a dopaminergic agonist relatively specific for the D2 receptor and much longer-acting than other dopamine agonists. We conducted a randomized, placebo-controlled, double-blind study of cabergoline in 188 levodopa/carbidopa-treated patients
Hutton, J. T., Rodnitzky, R. L., Pahwa, R., Hiner, B. C., Waters, C. H., Lieberman, Abraham N., Hurtig, H. I., Adler, C. H., Morris, J. L., Ahlskog, J. E., Stern, M. B., Muenter, M. D., Koller, W. C., Pfeiffer, R. F.   +13 more
core   +1 more source

Spontaneous reduction of prolactinoma post cabergoline withdrawal

, 2012
Prolactinomas are common pituitary tumors usually highly responsive to dopamine agonists. Around 70-90% of the prolactinomas exhibit decrease in tumor size, though variably with these agents.
Deepak Kothari, Anil Taneja, Smita Manchanda, Bindu Kulshreshtha, Sampath Kumar Venkatesh   +4 more
core   +1 more source

Case Report: Reversible cabergoline-associated cardiac valvulopathy post drug discontinuation [v1; ref status: indexed, http://f1000r.es/2jm]

F1000Research, 2014
We present a case of a 21 year old male patient diagnosed with a 2.2 cm prolactin-secreting adenoma in contact with the optic chiasm. The patient was treated with up to 6mg/week of cabergoline (total cumulative dose 814 mg) and developed mild ...
Chris G. Yedinak, Shirley McCartney, Troy H. Dillard, Kevin S. Wei, Maria Fleseriu   +4 more
doaj   +1 more source